The CD4 T cell response to respiratory syncytial virus infection

Immunologic Research

Volumn 59, Issue 1-3, 2014, Pages 109-117

  Christiaansen, Allison F ^a   Knudson, Cory J ^a   Weiss, Kayla A ^a   Varga, Steven M ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

CD4 T cell; IL 10; RSV; Th2; Treg; Vaccine

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; PARAINFLUENZA VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ARTIFICIAL VENTILATION; BRONCHIOLITIS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RESPONSE; GENETIC SUSCEPTIBILITY; HELPER CELL; HUMAN; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFLAMMATORY CELL; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TH17 CELL; TH2 CELL; TH9 CELL; VACCINATION; VIRAL CLEARANCE; ANIMAL; ART; FEMALE; GENETICS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INFANT; MALE; PATHOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ANIMALS; CYTOKINES; FEMALE; HUMANS; INFANT; MALE; PORTRAITS AS TOPIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; VACCINATION;

EID: 84905718668     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8540-1     Document Type: Review

References (71)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. The Lancet. 2010;375(9725):1545-55. doi:10.1016/S0140-6736(10)60206-1.
2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543-6. (Pubitemid 16120909)
3. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J. 2012;31(1):5-9. doi:10.1097/INF.0b013e31822e68e6.
4. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. 2007;20(1):108-19. doi:10.1038/modpathol.3800725. (Pubitemid 44967956)
5. Kim HW, Leikin SL, Arrobio J, Brandt CD, Chanock RM, Parrott RH. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res. 1976;10(1):75-8. doi:10.1203/00006450- 197601000-00015.
6. Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia - RSV recombinants or RSV. Vaccine. 1992;10(7):475-84.
7. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC 3rd, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalinin-activated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol. 1994;68(8):5321-5. (Pubitemid 24226607)
8. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest. 1991;88(3):1026-33. doi:10.1172/ jci115362.
9. You D, Marr N, Saravia J, Shrestha B, Lee GI, Turvey SE, et al. IL-4Rα on CD4+ T cells plays a pathogenic role in respiratory syncytial virus reinfection in mice infected initially as neonates. J Leukoc Biol. 2013;93(6):933-42. doi:10.1189/jlb.1012498.
10. Taylor S, Bryson YJ. Impaired production of gamma-interferon by newborn cells in vitro is due to a functionally immature macrophage. J Immunol. 1985;134(3):1493-7. (Pubitemid 15135912)
11. Garofalo RP, Patti J, Hintz KA, Hill V, Ogra PL, Welliver RC. Macrophage inflammatory protein-1a (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis. 2001;184(4):393-9. doi:10.1086/322788. (Pubitemid 32718501)
12. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2003;168(6):633-9. doi:10.1164/rccm.200210-1148OC. (Pubitemid 37175965)
13. Murai H, Terada A, Mizuno M, Asai M, Hirabayashi Y, Shimizu S, et al. IL-10 and RANTES are elevated in nasopharyngeal secretions of children with respiratory syncytial virus infection. Allergol Int. 2007;56(2):157-63. doi:10.2332/allergolint.O-06-454. (Pubitemid 46984244)
14. RomÁN M, Calhoun WJ, Hinton KL, AvendaÑO LF, Simon V, Escobar AM, et al. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am J Respir Crit Care Med. 1997;156(1):190-5. doi:10.1164/ajrccm.156.1.9611050. (Pubitemid 27293187)
15. Pinto RA, Arredondo SM, Bono MR, Gaggero AA, Diaz PV. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol. Pediatrics. 2006;117(5):e878-86. doi:10.1542/peds.2005-2119. (Pubitemid 46074635)
16. Brandenburg AH, Kleinjan A, van het Land B, Moll HA, Timmerman HH, de Swart RL, et al. Type 1-like immune response is found in children with respiratory syncytial virus infection regardless of clinical severity. J Med Virol. 2000;62(2):267-77. doi:10.1002/1096-9071(200010)62:2〈267:: AID-JMV20〉3.0.CO;2-8.
17. Tabarani CM, Bonville CA, Suryadevara M, Branigan P, Wang D, Huang D, et al. Novel inflammatory markers, clinical risk factors, and virus type associated with severe respiratory syncytial virus infection. Pediatr Infect Dis J. 2013;. doi:10.1097/INF.0b013e3182a14407.
18. Lukacs NW, Moore ML, Rudd BD, Berlin AA, Collins RD, Olson SJ, et al. Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am J Pathol. 2006;169(3):977-86. doi:10.2353/ajpath.2006.051055. (Pubitemid 44411960)
19. Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, et al. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol. 2011;85(12):5782-93. doi:10.1128/jvi.01693-10.
20. Tekkanat KK, Maassab HF, Cho DS, Lai JJ, John A, Berlin A, et al. IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent. J Immunol. 2001;166(5):3542-8. (Pubitemid 33117359)
21. Kaiko GE, Phipps S, Angkasekwinai P, Dong C, Foster PS. NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25. J Immunol. 2010;185(8):4681-90. doi:10.4049/jimmunol. 1001758.
22. Durant LR, Makris S, Voorburg CM, Loebbermann J, Johansson C, Openshaw PJM. Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J Virol. 2013;87(20):10946-54. doi:10.1128/JVI.01295-13JVI.01295-13.
23. Soroosh P, Doherty TA. Th9 and allergic disease. Immunology. 2009;127(4):450-8. doi:10.1111/j.1365-2567.2009.03114.x.
24. Dodd JS, Lum E, Goulding J, Muir R, Van Snick J, Openshaw PJM. IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. J Immunol. 2009;183(11):7006-13. doi:10.4049/jimmunol.0900085.
25. McNamara PS, Flanagan BF, Baldwin LM, Newland P, Hart CA, Smyth RL. Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus bronchiolitis. The Lancet. 2004;363(9414):1031-7. doi:10.1016/S0140-6736(04)15838-8. (Pubitemid 38410776)
26. Schuurhof A, Bont L, Siezen CL, Hodemaekers H, van Houwelingen HC, Kimman TG, et al. Interleukin-9 polymorphism in infants with respiratory syncytial virus infection: an opposite effect in boys and girls. Pediatr Pulmonol. 2010;45(6):608-13. doi:10.1002/ppul.21229.
27. Oboki K, Ohno T, Saito H, Nakae S. Th17 and allergy. Allergol Int. 2008;57(2):121-34. doi:10.2332/allergolint.R-07-160. (Pubitemid 351897666)
28. Mukherjee S, Lindell DM, Berlin AA, Morris SB, Shanley TP, Hershenson MB, et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol. 2011;179(1):248-58. doi:10.1016/j.ajpath.2011.03.003.
29. Chen Y, Thai P, Zhao Y-H, Ho Y-S, DeSouza MM, Wu R. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem. 2003;278(19):17036-43. doi:10.1074/jbc.M210429200. (Pubitemid 36799579)
30. Fujisawa T, Chang MM-J, Velichko S, Thai P, Hung L-Y, Huang F, et al. NF-κB mediates IL-1β-and IL-17A-induced MUC5B expression in airway epithelial cells. Am J Respir Cell Mol Biol. 2011;45(2):246-52. doi:10.1165/rcmb.2009-0313OC.
31. Song C, Luo L, Lei Z, Li B, Liang Z, Liu G, et al. IL-17-producing alveolar macrophages mediate allergic lung inflammation related to asthma. J Immunol. 2008;181(9):6117-24.
32. Scanlon ST, McKenzie ANJ. Type 2 innate lymphoid cells: new players in asthma and allergy. Curr Opin Immunol. 2012;24(6):707-12. doi:10.1016/j.coi. 2012.08.009.
33. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol. 1994;10(5):471-80. doi:10.1165/ajrcmb.10. 5.8179909.
34. Ying S, Humbert M, Barkans J, Corrigan CJ, Pfister R, Menz G, et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol. 1997;158(7):3539-44. (Pubitemid 127484076)
35. Fulton RB, Meyerholz DK, Varga SM. Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J Immunol. 2010;185(4):2382-92. doi:10.4049/jimmunol.1000423.
36. + natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol. 2010;84(17):8790-8. doi:10.1128/jvi.00796- 10.
37. Liu J, Ruckwardt TJ, Chen M, Johnson TR, Graham BS. Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model. J Virol. 2009;83(10):4934-41. doi:10.1128/jvi.02140-08.
38. Loebbermann J, Thornton H, Durant L, Sparwasser T, Webster KE, Sprent J, et al. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol. 2012;5(2):161-72. doi:10.1038/mi.2011.62.
39. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600-3. doi:10.1126/science.1202947.
40. Weiss KA, Christiaansen AF, Fulton RB, Meyerholz DK, Varga SM. Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection. J Immunol. 2011;187(6):3145-54. doi:10.4049/jimmunol.1100764.
41. Loebbermann J, Schnoeller C, Thornton H, Durant L, Sweeney NP, Schuijs M, et al. IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice. PLoS ONE. 2012;7(2):e32371. doi:10.1371/journal.pone.0032371.
42. Sun J, Cardani A, Sharma AK, Laubach VE, Jack RS, Müller W, et al. Autocrine regulation of pulmonary inflammation by effector T-cell derived IL-10 during infection with respiratory syncytial virus. PLoS Pathog. 2011;7(8):e1002173. doi:10.1371/journal.ppat.1002173.
43. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated non-regulatory CD4+ T cells. Eur J Immunol. 2007;37(1):129-38. doi:10.1002/eji.200636435. (Pubitemid 46128793)
44. Ruckwardt TJ, Bonaparte KL, Nason MC, Graham BS. Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J Virol. 2009;83(7):3019-28. doi:10.1128/JVI.00036-09.
45. Everard ML, Swarbrick A, Wrightham M, McIntyre J, Dunkley C, James PD, et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child. 1994;71(5):428-32. (Pubitemid 24349852)
46. Bem RA, Bos AP, Bots M, Wolbink AM, van Ham SM, Medema JP, et al. Activation of the granzyme pathway in children with severe respiratory syncytial virus infection. Pediatr Res. 2008;63(6):650-5. doi:10.1203/PDR. 0b013e31816fdc32.
47. McNamara PS, Ritson P, Selby A, Hart CA, Smyth RL. Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis. Arch Dis Child. 2003;88(10):922-6. (Pubitemid 37194053)
48. Schuurhof A, Janssen R, de Groot H, Hodemaekers HM, de Klerk A, Kimpen JL, et al. Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze. Respir Res. 2011;12:121. doi:10.1186/1465-9921-12-121.
49. Sheeran P, Jafri H, Carubelli C, Saavedra J, Johnson C, Krisher K, et al. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J. 1999;18(2):115-22. (Pubitemid 29101883)
50. Hoebee B, Bont L, Rietveld E, van Oosten M, Hodemaekers HM, Nagelkerke NJ, et al. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis. J Infect Dis. 2004;189(2):239-47. doi:10.1086/380908. (Pubitemid 38147247)
51. Wilson J, Rowlands K, Rockett K, Moore C, Lockhart E, Sharland M, et al. Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis. J Infect Dis. 2005;191(10):1705-9. doi:10.1086/429636. (Pubitemid 40656759)
52. Lazarus R, Klimecki WT, Palmer LJ, Kwiatkowski DJ, Silverman EK, Brown A, et al. Single-nucleotide polymorphisms in the interleukin-10 gene: differences in frequencies, linkage disequilibrium patterns, and haplotypes in three United States ethnic groups. Genomics. 2002;80(2):223-8. (Pubitemid 36197964)
53. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422-34.
54. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969;89(4):435-48.
55. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89(4):405-21.
56. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89(4):449-63.
57. Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol. 1986;57(3):721-8. (Pubitemid 16143949)
58. Vaux-Peretz F, Meignier B. Comparison of lung histopathology and bronchoalveolar lavage cytology in mice and cotton rats infected with respiratory syncytial virus. Vaccine. 1990;8(6):543-8.
59. Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC 3rd, Sotnikov AV, et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol. 1992;66(12):7444-51.
60. Johnson TR, Parker RA, Johnson JE, Graham BS. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol. 2003;170(4):2037-45. (Pubitemid 36197425)
61. Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, Blanco JC. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine. 2006;24(23):5027-35. doi:10.1016/j.vaccine.2006.03.064. (Pubitemid 43782692)
62. Johnson TR, Rao S, Seder RA, Chen M, Graham BS. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine. 2009;27(23):3045-52. doi:10.1016/j.vaccine.2009.03. 026.
63. Loebbermann J, Durant L, Thornton H, Johansson C, Openshaw PJ. Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. Proc Natl Acad Sci USA. 2013;110(8):2987-92. doi:10.1073/pnas.12175801101217580110.
64. Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol. 1992;4(4):493-500.
65. Openshaw PJ, Anderson K, Wertz GW, Askonas BA. The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. J Virol. 1990;64(4):1683-9. (Pubitemid 20104906)
66. Varga SM, Wissinger EL, Braciale TJ. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J Immunol. 2000;165(11):6487-95.
67. Varga SM, Wang X, Welsh RM, Braciale TJ. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4+ T cells. Immunity. 2001;15(4):637-46. (Pubitemid 33016448)
68. Castilow EM, Legge KL, Varga SM. Cutting edge: eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J Immunol. 2008;181(10):6692-6. doi:10.4049/jimmunol.181.10.6692.
69. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009;15(1):34-41. doi:10.1038/nm.1894.
70. Olson MR, Varga SM. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol. 2007;179(8):5415-24. doi:10.4049/jimmunol. 179.8.5415.
71. Olson MR, Hartwig SM, Varga SM. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J Immunol. 2008;181(11):7958-68. doi:10.4049/jimmunol.181.11.7958.